Clinical Trials Browser

NCT03110978 2026-04-16

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Neuroendocrine

NCT06523621 2026-04-16

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Phase 2 Active not recruiting

1 enrolled

Plasma cell

Multiple Myeloma

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

880 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03776487 2026-04-15

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Phase 2 Active not recruiting

32 enrolled

Gastrointestinal

Clinical Stage 0 Gastric Cancer AJCC v8

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Phase 2 Active not recruiting

6 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04957615 2026-04-15

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Phase 2 Active not recruiting

16 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05347212 2026-04-15

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Phase 2 Active not recruiting

30 enrolled

Tumor-Agnostic

Carcinoma

NCT06638931 2026-04-15

ANTARES

Phase 2 Recruiting

28 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther solid neoplasmSarcomaThoracic

Urachal adenocarcinoma, Urachal cancer, Fibrolamellar hepatocellular carcinoma, Secretory breast carcinoma, Carcinoma, Ovarian Epithelial, Adrenal Gland Neoplasms, Anus Neoplasms, Biliary Tract Neoplasms, Carcinosarcoma, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Fibrosarcoma, Gallbladder Neoplasms, Granulosa Cell Tumor, Hemangiosarcoma, Leiomyosarcoma, Mesothelioma, Neuroblastoma, Parathyroid Neoplasms, Penile Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Thyroid Neoplasms, Trophoblastic Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Hepatoblastoma, Endodermal Sinus Tumor, Neuroectodermal Tumors, Primitive, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Neurofibrosarcoma, Hemangioblastoma, Neuroendocrine Tumors

Clinical Trials

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

PSI-Immune

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

ANTARES

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

N'FORCE

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

NIVO1002024

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

SAMURAI

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

NOCANO

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

CHAMP

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

EXACT

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

TAPUR

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

REGINA

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

NICHE